Richard Mabe is the new executive director of Waltonwood Cary Parkway, a senior community in Cary, N.C.
Nursing homes seek overdue Medicaid managed care payments
By
Kimberly Marselas
Dec 21, 2017
Several managed care organizations providing Medicaid coverage in Illinois are being accused in federal court of taking too long to get payments to skilled nursing facilities.
Skin closure system debuts
Dec 20, 2017
Chemence Medical Inc. announced it has received Food and Drug Administration clearance to market and sell Exofin Fusion®, a new skin closure system for medium to large wounds.
Ventas said it supports Kindred acquisition
Dec 20, 2017
Ventas Inc. said it supports the acquisition of Kindred Healthcare by TPG Capital, Welsh, Carson, Anderson & Stowe, and Humana Inc.
Kindred confirms its sale for $4.1 billion in multi-firm deal
By
Kimberly Marselas
Dec 20, 2017
Kindred Healthcare announced Tuesday that its board has agreed to an acquisition by Humana Inc. and two private equity partners in all cash deal.
Reports: Humana-Kindred merger on the table
By
Kimberly Marselas
Dec 19, 2017
Kindred assets could be divided into separate home care and facility lines.
Skilled nursing occupancy hits 5-year low
By
Kimberly Marselas
Dec 15, 2017
Occupancy at the nation’s skilled nursing facilities dropped to a five-year low of 81.6% during the third quarter of 2017, according to a new report.
Elf solves LTC staffing crisis
By
Gary Tetz
Dec 14, 2017
November 28 is ruined for me now. Thanks, CMS. For years, I’ve been celebrating it as the fateful day in 1443 when Albanian George Kastriotis Skanderbeg and his forces liberated Kruja in Middle Albania...
Tech execs guilty of conspiring to fill nursing home prescriptions with recycled drugs
By
Kimberly Marselas
Dec 14, 2017
A subsidiary of a pharmacy chain near Pittsburgh pleaded guilty Tuesday in a conspiracy scheme described by prosecutors as an attempt to recycle unused medications.
Additional review time requested for ulcerative colitis drug
Dec 13, 2017
Pfizer Inc. said Tuesday the Food and Drug Administration has extended the action date by three months for the supplemental New Drug Application (sNDA) for XELJANZ®(tofacitinib) .